News for Pharming Group N.V. (PHGUF)

**media[638710]**

Pharming Group N.V. (NASDAQ:PHAR) Q1 2025 Earnings Conference Call May 8, 2025 7:30 AM ETCompany ParticipantsFabrice Chouraqui – CEOStephen Toor – CCOAnurag...

**media[618411]**

Pharming Group (PHARM) to present results from Phase III clinical trials on leniolisib for pediatric APDS at the 2025 Clinical Immunology Society Meeting.

**media[605616]**

Pharming Group N.V. (Euronext: PHARM/Nasdaq: PHAR) to release Q1 2025 financial results on May 8, 2025. The earnings report will cover the fiscal period

**media[603918]**

Joenja® (leniolisib) receives positive recommendation from NICE, becoming the first and only treatment for APDS approved within the NHS. The approval i

**media[602574]**

**media[584601]**

**media[579144]**

**media[571508]**

Full-Year Revenue: Increased by 21% to $297 million.RUCONEST Revenue: Grew 11% to $252 million.Joenja Revenue: Increased by 147% to $45 million.Q4 Revenue Grow

Pharming Group N.V. (NASDAQ:PHAR) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ETCompany ParticipantsFabrice Chouraqui - CEOStephen Toor -...

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Thursday. Shares of G-III Apparel Group, Ltd. GIII gained 13.9% to $28.87 after t...

**media[565046]**

**media[553050]**

**media[551733]**

**media[546147]**